Search clinical trials for: 18-056

Total 7438 results

Celgene

Completed

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Korea, Republic of, United States, Belgium, Israel, Netherlands, Australia, Germany, Hungary, New Zealand, Italy, Canada, Bulgaria, Croatia, United Kingdom, Argentina, Austria, Belarus, Czechia, Georgia, Moldova, Republic of, Po... and more
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis (SELECTION)

Ulcerative Colitis

United States, Netherlands, Israel, Spain, Taiwan, Germany, Australia, Italy, Hong Kong, India, Singapore, Canada, Korea, Republic of, United Kingdom, New Zealand, Ireland, France, Poland, Japan, Switzerland, Croatia, Belgium, Malaysia and more
Galapagos NV
Gilead Sciences

Active, not recruiting

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (SELECTIONLTE)

Ulcerative Colitis

United States, Netherlands, Israel, Spain, Taiwan, Australia, Italy, Hong Kong, Singapore, Korea, Republic of, Canada, Germany, United Kingdom, New Zealand, Ireland, Poland, Romania, Croatia, Belgium, Japan, India, Malaysia, Sweden, F... and more
Boehringer Ingelheim
Pfizer

Completed

Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example

Pulmonary Disease, Chronic Obstructive

Germany
AbbVie

Active, not recruiting

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) (SEQUENCE)

Crohn's Disease (CD)

United States, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slovakia, South... and more
Novartis Pharmaceuticals

Terminated

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) (ALTITUDE)

Cardiovascular Disease | Type 2 Diabetes Mellitus

Spain, China, United States, Belgium, Colombia, South Africa, Italy, United Kingdom, Germany, Hungary, Japan, Taiwan, Turkey, Netherlands, Greece, Switzerland, Austria, France, Thailand, Argentina, Canada, Singapore, Lithuania, Sweden, ... and more
Novo Nordisk A/S

Completed

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT)

Obesity | Overweight

United States, France, Spain, Taiwan, United Kingdom, Germany, India, Brazil, Canada, Japan, Malaysia, Russian Federation, Australia, Norway, Mexico, Netherlands, Portugal, Hungary, Italy, Austria, Greece, South Africa, Turkey, Finland, Puerto Rico and more
Kowa Research Institute, Inc.
Brigham and Women's Hospital

Terminated

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) (PROMINENT)

Dyslipidemia | Type2 Diabetes

United States, Spain, Canada, Hungary, Netherlands, Brazil, Bulgaria, Poland, Israel, Russian Federation, Ukraine, Denmark, Czechia, South Africa, Argentina, Mexico, United Kingdom, Romania, Germany, India, Slovakia, Japan, Colombia, ... and more
Shire

Completed

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)

Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
Hoffmann-La Roche

Terminated

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies (COTTONWOOD)

Ulcerative Colitis

Israel, Spain, United States, United Kingdom, Belgium, Korea, Republic of, Canada, Australia, Austria, Czechia, France, Italy, Netherlands, New Zealand, Russian Federation, Hungary, Singapore, India, Portugal, Serbia, Hong Kong, B... and more
Boehringer Ingelheim

Completed

Long-term Observation PMS for Afatinib

Carcinoma, Non-Small-Cell Lung

Japan
Arena Pharmaceuticals

Completed

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis (ELEVATE UC 12)

Ulcerative Colitis

United States, Spain, Israel, Netherlands, Australia, Korea, Republic of, Czechia, Italy, Russian Federation, Croatia, Portugal, Serbia, Belarus, Canada, Georgia, Hungary, Ukraine, Germany, Poland, Belgium, Turkey, Japan, Thailand, India and more
Novartis Pharmaceuticals

Completed

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

Cardiovascular Disease and Lipoprotein(a)

China, Germany, United States, Colombia, South Africa, Italy, Spain, Belgium, Egypt, Hungary, Taiwan, Turkey, Japan, Netherlands, Australia, Austria, Canada, Czechia, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Th... and more
GlaxoSmithKline
The TIMI Study Group

Completed

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52)

Acute Coronary Syndrome

United States, France, Netherlands, Ukraine, Germany, Taiwan, Bulgaria, Hungary, Poland, Russian Federation, Argentina, Belgium, Peru, Philippines, Sweden, Thailand, Israel, Spain, Korea, Republic of, Australia, Czechia, Japan, New... and more
GlaxoSmithKline

Completed

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk (REDUCE)

Neoplasms, Prostate

United States, Australia, France, Germany, Spain, Bulgaria, Estonia, Italy, Poland, Netherlands, Belgium, United Kingdom, Canada, Denmark, Ukraine, Finland, Latvia, Russian Federation, Greece, Slovenia, Brazil, Mexico, Slovakia, Japan, Puerto... and more
Bristol-Myers Squibb

Completed

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

Atrial Fibrillation | Atrial Flutter

Australia, Brazil, China, France, Germany, India, Italy, Korea, Republic of, Mexico, Russian Federation, Sweden, Taiwan, Turkey, United States, Hong Kong, Spain, Argentina, Canada, Puerto Rico, Colombia, Denmark, Austria, Belgium, Hun... and more
AstraZeneca

Completed

European Study of Cardiovascular Risk (EURIKA)

Smoking | Hypertension | Obesity | Diabetes | Hyperlipidemia | Cardiovascular Risk Factors

Sweden, France, Russian Federation, Spain, Turkey, United Kingdom, Germany, Norway, Austria, Belgium, Switzerland, Greece
Janssen Research & Development, LLC

Active, not recruiting

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

Crohn's Disease

United States, Israel, Japan, Belgium, Lebanon, Taiwan, Netherlands, Russian Federation, Korea, Republic of, Jordan, France, Portugal, Greece, Canada, Germany, Malaysia, Belarus, Latvia, Poland, Australia, Italy, Croatia, Turkey, China, United Kingdom and more
Galapagos NV
Gilead Sciences

Terminated

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease (DIVERSITYLTE)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, Italy, India, Singapore, Portugal, France, Malaysia, New Zealand, Ireland, Poland, Romania, Japan, Croatia, Iceland, United... and more
Shire

Completed

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Crohn's Disease | Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
Galapagos NV
Gilead Sciences

Completed

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease (DIVERSITY1)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, France, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, United Kingdom, Italy, India, Singapore, Portugal, Malaysia, New Zealand, Serbia, Ireland, Poland, Romania, Japan, ... and more
AbbVie

Active, not recruiting

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, New... and more
AbbVie

Completed

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)

United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Nether... and more
AbbVie

Active, not recruiting

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies (U-EXCEL)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
AbbVie

Completed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more
AbbVie

Active, not recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic... and more
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea,... and more
AbbVie

Active, not recruiting

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
AbbVie

Completed

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Boehringer Ingelheim

Completed

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study

Hypertension

France
Boehringer Ingelheim

Completed

Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region

Pulmonary Disease, Chronic Obstructive

Croatia, Poland, Romania, Russian Federation, Slovakia, Slovenia
Boehringer Ingelheim

Completed

TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium

Hypertension

Belgium
Boehringer Ingelheim

Completed

Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

Atrial Fibrillation

Japan
Boehringer Ingelheim

Completed

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Atrial Fibrillation

Germany
Pfizer

Terminated

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2)

Cardiovascular Disease

United States, Finland, Netherlands, Spain, Belgium, Germany, Czechia, Switzerland, Denmark, Australia, United Kingdom, Korea, Republic of, Hungary, Israel, Poland, Taiwan, Mexico, Turkey, Ireland, Canada, New Zealand, South Africa, Brazi... and more
Pfizer

Terminated

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Cardiovascular Disease

Finland, United States, Netherlands, Spain, Korea, Republic of, China, Israel, Belgium, Germany, Australia, Czechia, Taiwan, Denmark, United Kingdom, Hungary, Poland, France, Mexico, Turkey, Canada, New Zealand, Colombia, Switzerland, Irelan... and more

Search clinical trials for: 18-056

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations